Efficacy, tolerability, and biologic activity of a novel regimen of tremelimumab (T) in combination with durvalumab (D) for patients (pts) with advanced hepatocellular carcinoma (aHCC).

被引：0

作者：

Kelley, Robin Kate

Sangro, Bruno

Harris, William Proctor

Ikeda, Masafumi

Okusaka, Takuji

Kang, Yoon-Koo

Qin, Shukui

Tai, Wai Meng David

Lim, Ho Yeong

Yau, Thomas

Yong, Wei-Peng

Cheng, Ann-Lii

Gasbarrini, Antonio

De Braud, Filippo G.

Bruix, Jordi

Borad, Mitesh J.

He, Philip

Negro, Alejandra

Kudo, Masatoshi

Abou-Alfa, Ghassan K.

机构：

[1] Univ Calif San Francisco, San Francisco, CA 94143 USA

[2] Clin Univ Navarra, Pamplona, Spain

[3] Biomed Res Networking Ctr Hepat & Digest Dis, Pamplona, Spain

[4] Univ Washington, Sch Med, Seattle, WA USA

[5] Natl Canc Ctr Hosp East, Kashiwa, Chiba, Japan

[6] Natl Canc Ctr, Dept Hepatobiliary & Pancreat Oncol, Tokyo, Japan

[7] Asan Med Ctr, Seoul, South Korea

[8] Jinling Hosp, Canc Ctr, Nanjing, Peoples R China

[9] Natl Canc Ctr Singapore, Singapore, Singapore

[10] Sungkyunkwan Univ, Samsung Med Ctr, Dept Med, Sch Med, Seoul, South Korea

[11] Univ Hong Kong, Queen Mary Hosp, Hong Kong, Peoples R China

[12] Natl Univ Canc Inst, Singapore, Singapore

[13] Natl Taiwan Univ Hosp, Taipei, Taiwan

[14] Natl Taiwan Univ, Canc Ctr, Taipei, Taiwan

[15] Univ Cattolica Sacro Cuore, Milan, Italy

[16] Fdn IRCCS Ist Nazl Tumori, Dept Med Oncol & Hematol, Milan, Italy

[17] Clin & Prov Hosp Barcelona, Barcelona, Spain

[18] Mayo Clin, Canc Ctr, Scottsdale, AZ USA

[19] AstraZeneca, Gaithersburg, MD USA

[20] Kindai Univ, Dept Gastroenterol & Hepatol, Fac Med, Osaka, Japan

[21] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

4508

引用

页数：2

共 50 条

[1] The novel regimen of tremelimumab in combination with durvalumab provides a favorable safety profile and clinical activity for patients with advanced hepatocellular carcinoma
Kelley, R.
Kudo, M.
Harris, W.
Ikeda, M.
Okusaka, T.
Kang, Y.
Qin, S.
Tai, D.
Lim, H.
Yau, T.
Yong, W.
Cheng, A.
Gasbarrini, A.
de Braud, F.
Bruix, J.
Borad, M.
Standifer, N.
He, P.
Negro, A.
Vlahovic, G.
Sangro, B.
Abou-Alfa, G.
ANNALS OF ONCOLOGY, 2020, 31 : S233 - S234
[2] Low immunogenicity and favorable safety seen with novel regimen of tremelimumab (T) plus durvalumab (D) in patients (pts) with unresectable hepatocellular carcinoma (uHCC)
Kelley, R. K.
Negro, A.
Chen, C.
Ali, S.
Standifer, N.
Watras, M.
Evans, B.
Abou-Alfa, G. K.
ANNALS OF ONCOLOGY, 2020, 31 : S1429 - S1429
[3] COST-EFFECTIVENESS OF TREMELIMUMAB OR TREMELIMUMAB IN COMBINATION WITH DURVALUMAB VS DURVALUMAB AS TREATMENT OF ADVANCED HEPATOCELLULAR CARCINOMA
Tang, T.
Shi, L.
VALUE IN HEALTH, 2023, 26 (06) : S138 - S138
[4] T-cell receptor pharmacodynamics associated with survival and response to tremelimumab (T) in combination with durvalumab (D) in patients (pts) with unresectable hepatocellular carcinoma (uHCC).
McCoon, Patricia
Lee, Young S.
Kelley, Robin Kate
Guthrie, Violeta Beleva
Wu, Song
Bien, Stephanie A.
Negro, Alejandra
He, Philip
Kurland, John
Barrett, J. Carl
Pilataxi, Fernanda
Ching, Steven
Abou-Alfa, Ghassan K.
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[5] Durvalumab Plus Tremelimumab: A Novel Combination Immunotherapy for Unresectable Hepatocellular Carcinoma
Kudo, Masatoshi
LIVER CANCER, 2022, 11 (02) : 87 - 93
[6] Evaluation of safety and tolerability of durvalumab (D) and tremelimumab (T) in combination with first-line chemotherapy in patients (pts) with esophageal squamous-cell carcinoma (ESCC).
Lee, Dae Ho
Kim, HyeRyun
Keam, Bhumsuk
Kato, Ken
Kuboki, Yasutoshi
Vlahovic, Gordana
Takahashi, Osamu
Fitts, David
Ahn, Myung-Ju
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
[7] Safety and efficacy of durvalumab in combination with tremelimumab, durvalumab monotherapy, and tremelimumab monotherapy in patients with advanced gastric cancer.
Kelly, Ronan Joseph
Lee, Jeeyun
Bang, Yung-Jue
Almhanna, Khaldoun
Murphy, Mariela A. Blum
Catenacci, Daniel V. T.
Chung, Hyun Cheol
Wainberg, Zev A.
Gibson, Michael
Lee, Keun Wook
Bendell, Johanna C.
Denlinger, Crystal S.
Brohawn, Philip Z.
He, Peng
McDevitt, Jennifer
Englert, Judson
Ku, Geoffrey Yuyat
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[8] Evaluation of safety and tolerability of durvalumab (D) with or without tremelimumab (T) in patients (pts) with biliary tract cancer (BTC).
Ioka, Tatsuya
Ueno, Makoto
Oh, Do-Youn
Fujiwara, Yutaka
Chen, Jen-Shi
Doki, Yuichiro
Mizuno, Nobumasa
Park, Keunchil
Asagi, Akinori
Hayama, Manabu
Nii, Masahiro
Komuro, Keiko
Sugimoto, Mariko
Vlahovic, Gordana
Ikeda, Masafumi
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
[9] Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma
Duffy, Austin G.
Ulahannan, Susanna V.
Makorova-Rusher, Oxana
Rahma, Osama
Wedemeyer, Heiner
Pratt, Drew
Davis, Jeremy L.
Hughes, Marybeth S.
Heller, Theo
ElGindi, Mei
Uppala, Ashish
Korangy, Firouzeh
Kleiner, David E.
Figg, William D.
Venzon, David
Steinberg, Seth M.
Venkatesan, Aradhana M.
Krishnasamy, Venkatesh
Abi-Jaoudeh, Nadine
Levy, Elliot
Wood, Brad J.
Greten, Tim F.
JOURNAL OF HEPATOLOGY, 2017, 66 (03) : 545 - 551
[10] Early reduction in circulating tumor DNA (ctDNA) and survival in gastric cancer patients (pts) treated with durvalumab (D), tremelimumab (T), or durvalumab in combination with tremelimumab (D plus T)
Brohawn, Philip Z.
Higgs, Brandon W.
Kuziora, Michael
Englert, Judson
Ranade, Koustubh
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)

← 1 2 3 4 5 →